iRobot receives FDA approval
iRobot Corp (IRBT), a leader in delivering robotic solutions, announced today that RP-VITA Remote Presence Robot has received 510(k) clearance by the US Food and Drug Administration (FDA) for use in hospitals. iRobot’s RP-VITA is the first autonomous navigation remote presence robot to receive FDA clearance.
Since the announcement was made, IRBT shares increased from $2.21, or 10.5%, to $23.32.
RP-VITA was developed by iRobot and InTouch Health and combines the latest in autonomous navigation and mobility technologies as well as state-of-the-art telemedicine and electronic health record integration.
In a nutshell, the robot will allow doctors to visit hospital patients remotely. They will be able to view and communicate with the patient via a high-tech iPad application.
According to iRobot, the FDA clearance states RP-VITA ‘can be used for active patient monitoring in pre-operative, peri-operative and post-surgical settings, including cardiovascular, neurological, prenatal, psychological and critical care assessments and examinations.’
This is the first robot to be cleared for everyday use in a hospital setting, sparking a new development in the way we access and communicate with medical professionals in the future.
How do you feel about iRobot’s latest clearance? Join the discussion on Twitter @HealthCareG
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”